Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes.

Matza LS, Boye KS, Currie BM, Paczkowski R, Lando LF, Mody R, Jordan J

Current medical research and opinion14 May 2018Cited by 23 (Europe PMC)

PMID29661026DOI10.1080/03007995.2018.1465903PepBankPUB-29661026

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneObservational studyOther
Among adults with type 2 diabetes, injection device experience scores were high for both the liraglutide and dulaglutide devices.
In plain wordsAdults with type 2 diabetes rated both the liraglutide and dulaglutide injection devices highly.
Peptide
Liraglutide
Outcome
Not applicableInjection device experience (DID-EQ item scores)
Study
n = 404
Outcome group
Patient-reported outcomes · Metabolic and weight
Measurements
DID-EQ item score
3.48 to 3.9 points
both treatments, 4 point scale
Source sentences
Summary
Mean DID-EQ item scores for both treatments were high, ranging from 3.48 to 3.90 on a 4 point scale.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 2 diabetes treated with liraglutide or dulaglutide were recruited from across the US.
Summary · context
Patients completed the Diabetes Injection Device Experience Questionnaire (DID-EQ) to rate their current injection device.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2966102601
02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In patients with diabetes, device experience ratings were high for both dulaglutide and liraglutide devices.
In plain wordsIn patients with diabetes, users rated both dulaglutide and liraglutide devices highly.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableInjection device experience ratings
Study
n = 404
Outcome group
Device usability · Whole body
Measurements
Item score
3.48 to 3.9 points
both devices on a 4 point scale
Source sentences
Summary
Mean DID-EQ item scores for both treatments were high, ranging from 3.48 to 3.90 on a 4 point scale.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 2 diabetes treated with liraglutide or dulaglutide were recruited from across the US.
Summary · context
Patients completed the Diabetes Injection Device Experience Questionnaire (DID-EQ) to rate their current injection device.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2966102605
03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In patients with diabetes, the dulaglutide device was linked to higher ease-of-use scores than the liraglutide device.
In plain wordsIn patients with diabetes, the dulaglutide device was linked to better ease-of-use ratings than the liraglutide device.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseEase of use
Study
n = 404
Comparator
Liraglutide injection device
Outcome group
Device usability · Whole body
Measurements
DID-EQ ease of use score
3.82 points
dulaglutide patients
DID-EQ ease of use score
3.73 points
liraglutide patients
Source sentences
Summary
ANCOVAs found significantly higher scores for dulaglutide than liraglutide on DID-EQ global items assessing ease of use (3.82 vs. 3.73, p = .040) and convenience (3.79 vs. 3.66, p = .004).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 2 diabetes treated with liraglutide or dulaglutide were recruited from across the US.
Summary · context
Patients completed the Diabetes Injection Device Experience Questionnaire (DID-EQ) to rate their current injection device.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2966102606
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In patients with diabetes, the dulaglutide device was linked to higher convenience scores than the liraglutide device.
In plain wordsIn patients with diabetes, the dulaglutide device was linked to better convenience ratings than the liraglutide device.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseConvenience
Study
n = 404
Comparator
Liraglutide injection device
Outcome group
Device usability · Whole body
Measurements
DID-EQ convenience score
3.79 points
dulaglutide patients
DID-EQ convenience score
3.66 points
liraglutide patients
Source sentences
Summary
ANCOVAs found significantly higher scores for dulaglutide than liraglutide on DID-EQ global items assessing ease of use (3.82 vs. 3.73, p = .040) and convenience (3.79 vs. 3.66, p = .004).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 2 diabetes treated with liraglutide or dulaglutide were recruited from across the US.
Summary · context
Patients completed the Diabetes Injection Device Experience Questionnaire (DID-EQ) to rate their current injection device.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2966102607
05HumanNot a test of Liraglutide aloneObservational studyOther
Among 58 adults with type 2 diabetes who had used both devices, more preferred the dulaglutide device than the liraglutide device on every item.
In plain wordsAmong 58 patients who used both devices, more preferred the dulaglutide device than the liraglutide device on every item.
Peptide
Liraglutide
Outcome
DecreaseDevice preference (DID-PQ)
Study
n = 58
Comparator
Dulaglutide injection device
Outcome group
Patient-reported outcomes · Metabolic and weight
Source sentences
Summary
Among the 58 patients who had used both devices, more patients reported a preference for the dulaglutide device than the liraglutide device on every item of the DID-PQ.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 2 diabetes treated with liraglutide or dulaglutide were recruited from across the US.
Summary · context
Patients completed the Diabetes Injection Device Experience Questionnaire (DID-EQ) to rate their current injection device.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2966102604
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Among patients who used both devices, more preferred the dulaglutide device than the liraglutide device on every questionnaire item.
In plain wordsAmong patients who used both devices, more preferred the dulaglutide device than the liraglutide device.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDevice preference
Study
n = 58
Comparator
Liraglutide injection device
Outcome group
Device usability · Whole body
Source sentences
Summary
Among the 58 patients who had used both devices, more patients reported a preference for the dulaglutide device than the liraglutide device on every item of the DID-PQ.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 2 diabetes treated with liraglutide or dulaglutide were recruited from across the US.
Summary · context
Patients completed the Diabetes Injection Device Experience Questionnaire (DID-EQ) to rate their current injection device.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2966102608
07HumanNot a test of Liraglutide aloneObservational studyOther
Among adults with type 2 diabetes, the liraglutide injection device scored significantly lower for ease of use than the dulaglutide device.
In plain wordsAdults with type 2 diabetes rated the liraglutide injection device slightly lower for ease of use than the dulaglutide device.
Peptide
Liraglutide
Outcome
DecreaseDID-EQ global item: ease of use
Study
n: not reported in source
Comparator
Dulaglutide injection device
Outcome group
Patient-reported outcomes · Metabolic and weight
Measurements
DID-EQ ease of use
3.73 points
liraglutide
DID-EQ ease of use
3.82 points
dulaglutide
Source sentences
Summary
ANCOVAs found significantly higher scores for dulaglutide than liraglutide on DID-EQ global items assessing ease of use (3.82 vs. 3.73, p = .040) and convenience (3.79 vs. 3.66, p = .004).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 2 diabetes treated with liraglutide or dulaglutide were recruited from across the US.
Summary · context
Patients completed the Diabetes Injection Device Experience Questionnaire (DID-EQ) to rate their current injection device.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2966102602
08HumanNot a test of Liraglutide aloneObservational studyOther
Among adults with type 2 diabetes, the liraglutide injection device scored significantly lower for convenience than the dulaglutide device.
In plain wordsAdults with type 2 diabetes rated the liraglutide injection device slightly lower for convenience than the dulaglutide device.
Peptide
Liraglutide
Outcome
DecreaseDID-EQ global item: convenience
Study
n: not reported in source
Comparator
Dulaglutide injection device
Outcome group
Patient-reported outcomes · Metabolic and weight
Measurements
DID-EQ convenience
3.66 points
liraglutide
DID-EQ convenience
3.79 points
dulaglutide
Source sentences
Summary
ANCOVAs found significantly higher scores for dulaglutide than liraglutide on DID-EQ global items assessing ease of use (3.82 vs. 3.73, p = .040) and convenience (3.79 vs. 3.66, p = .004).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 2 diabetes treated with liraglutide or dulaglutide were recruited from across the US.
Summary · context
Patients completed the Diabetes Injection Device Experience Questionnaire (DID-EQ) to rate their current injection device.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2966102603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes.

Summary

Results from this study8

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms

Keywords